zedie.wordpress.com
FDA approves subcutaneous trastuzumab for HER2+ breast cancer
Takeaway The FDA has approved a subcutaneous formulation of trastuzumab that strikingly reduces administration time in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Subcut…